Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2025)

Historic EBT Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to 108.45%.

  • Maravai Lifesciences Holdings' EBT Margin rose 1409400.0% to 108.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 113.31%, marking a year-over-year decrease of 2725600.0%. This contributed to the annual value of 100.89% for FY2024, which is 3146800.0% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' EBT Margin stood at 108.45%, which was up 1409400.0% from 156.39% recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBT Margin peaked at 885.05% during Q4 2023, and registered a low of 249.39% during Q3 2024.
  • For the 5-year period, Maravai Lifesciences Holdings' EBT Margin averaged around 29.84%, with its median value being 5.72% (2023).
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' EBT Margin surged by 8382200bps in 2023, and later crashed by -9665100bps in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBT Margin (Quarter) stood at 63.34% in 2021, then decreased by -26bps to 46.83% in 2022, then skyrocketed by 1790bps to 885.05% in 2023, then plummeted by -109bps to 81.46% in 2024, then plummeted by -33bps to 108.45% in 2025.
  • Its EBT Margin was 108.45% in Q3 2025, compared to 156.39% in Q2 2025 and 112.47% in Q1 2025.